Introducing the GI Genius™ AI Access™ platform
Accelerating AI innovation in healthcare
Accelerating AI innovation in healthcare
In collaboration with Cosmo Intelligent Medical Devices (IMD) and NVIDIA technology, we are excited to introduce the Innovation Center. This enables AI developers to train and validate next generation AI models through the GI Genius™ module.
Statements are prospective and do not necessarily represent the aspects of any future marketed product.
The Innovation Center was created for developers to design, test, and deploy new AI applications through a simulated environment of the GI Genius™ operating system.
Engage the talent of the AI developer community to partner in strategic business relationships
Access a virtual sandbox to test medical AI models in an environment that simulates the GI Genius™ module with NVIDIA capabilities.
*powered by NVIDIA
Accelerate AI innovation and scale development across medical AI applications
The AI developer community can directly contribute to accelerating AI for clinical care.
The value of the Innovation Center is to reduce time-to-market with the help of Cosmo IMD experience and services and accelerate development to a commercially available technology.
The Innovation Center is a potential solution for developers that have:
If the AI software is chosen, the Innovation Center will provide:
Cosmo IMD will facilitate the engagement at the Innovation Center to ensure the process is clear for those that want to contribute to advancements in healthcare.
The future distribution of the algorithm will be through GI Genius™ system which is managed by the Medtronic gastrointestinal business. Additional details will be available on the standard agreement terms.
Train the AI model with the data and the ground truth with the preferred Machine Learning framework (e.g., PyTorch).
Receive a user login at the Innovation Center to leverage the libraries and tools contained in the AI Access™ developer kit, which contains a software development kit to build the app that runs the trained model.
Test the application using the testing tools available in the AI Access™ developer kit.
All third-party algorithms that will be hosted by the GI Genius™ module are required to meet regulatory requirements and enter into a business agreement between Medtronic and Cosmo IMD.
The decision to move forward with an application will be determined by Cosmo IMD and/or Medtronic.
Use the AI Access™ developer kit on a PC or server to test the app to evaluate the functionality and performance.
Through the Innovation Center, access the cloud-based testing environment to virtually test the app on production hardware.
Secure an on-premise AI Access™ developer kit to test the model in the final stage of development.
The Innovation Center is designed to scale AI development and help accelerate new software as a medical device through regulatory requirements with feasible testing and strategic partnerships.
Medtronic strives to be a best-in-class artificial intelligence (AI) company – our vision is to help scale innovation and enable access to relevant and responsible AI solutions in healthcare.
We believe in our unique technology and expertise to bring new AI solutions to the marketplace.
Medtronic will develop the AI Access™ platform which will provide a set of solutions meant to enable and scale up the implementation of AI software innovation in the endoscopy suite. The AI Access™ platform will enable GI Genius™ module to become the go-to platform to host multiple AI software applications providing physicians the access to a suite of innovative solutions. It will enable Medtronic to enter strategic business agreements to expand the possibilities in the healthcare system.
Cosmo IMD developed the Innovation Center which will provide third-party developers with a sandbox to design and test medical AI software using a virtual version of the GI Genius™ module. The Innovation Center will enable third-party developers with a cloud-based platform to efficiently train and validate their own AI software with the intent to eventually distribute them through the GI Genius™ module. The Innovation Center is a way to accelerate innovation and bring AI-powered applications to the market faster.
Medtronic is committed to bringing innovative approaches to connecting the physician and patient to innovation. One of the fastest growing areas of medical technology development is the creation of AI software applications to improve patient outcomes. Developers are skilled at building AI software applications, but they often do not have the commercial channels or resources to commercialize the applications.
Our vision is to bring continuous solutions with our own GI Genius™ AI-assisted colonoscopy software that we distribute and market, to accelerate AI innovation through bringing additional regulated AI software to the healthcare space via new partnerships to be hosted on the GI Genius™ module.
Medtronic will manage business agreements with third-party developers to host newly developed AI software algorithms on the GI Genius™ module.
Once regulatory requirements are met, it is anticipated that any new AI software added to the GI Genius™ module will be an optional add-on for new and existing customers. The pricing model will be determined prior to market availability. Medtronic will sell the new third-party AI software directly to customers. Medtronic will facilitate an upgrade with the new AI software to the current GI Genius™ module at the customer’s site. Any existing customer that wants to acquire an add-on AI software be able to use their current GI Genius™ module.
Cosmo IMD will manage the Innovation Center to test and deploy AI algorithms through the GI Genius™ module through NVIDIA cloud-based technology and with an on-premises AI Access™ developer kit to accelerate the innovation process. Cosmo IMD is responsible for the technical review of new AI algorithm submission from third-party developers.
See additional details on how to be involved at the Cosmo IMD Innovation Center.
This new service is currently not available. However, in the future, all existing customers using GI Genius™ module for AI-assisted colonoscopy can have access to updated GI Genius™ software versions and subsequent new AI software algorithms. It will be up to the customer to opt-into a new additional payment for any additional AI software application once it becomes available.
It is anticipated that a software upgrade will enable existing GI Genius™ modules to support new AI Access™ platform capabilities. Further, any AI software algorithm added to the GI Genius™ module will follow all regulatory requirements in the local market. Medtronic will be the distributors of any future third-party AI software additions to the GI Genius™ module.
All new customers will be required to maintain the base model of the GI Genius™ module that includes the Medtronic marketed GI Genius™ AI-assisted colonoscopy software.
Medtronic and Cosmo IMD are in early access stages of this program. The companies have announced that the GI Genius™ module has the capability to host multiple AI software algorithms in an effort to solicit third-party developer engagement. There are currently no additional software algorithms available for marketing or commercialization on the GI Genius™ module.
Medtronic will announce the launch of any new AI software algorithms following once all regulatory requirements are met.
The implementation is not expected to change at this time. Medtronic and Cosmo IMD are always looking to improve the system and add value to customer.
Third-party developers potentially gain access to distribute their AI software solutions on the GI Genius™ module which is an existing regulated hardware platform with a large install base.
Cosmo IMD is managing the agreements with third-party developers related to technical aspects of testing and deployment of new AI software algorithms. In the future, Medtronic will manage the details of the commercial agreements with the third-party developers. Additional information will be provided at a later date.
The technology depicted is in development and is not commercialized or available for sale in any region. Any statements about functionality or features are forward looking in nature and do not necessarily represent the functionality of any eventually marketed product.
™* Third-party brands are trademarks of their respective owners.
Michael Wallace, Prateek Sharma, Pradeep Bhandari, James East, Giulio Antonelli, Cesare Hassan, et al. Impact of Artificial Intelligence on Miss Rate of Colorectal Neoplasia. Gastroenterology. 2022 Jul;163(1):295-304.e5.